We aim to complete the development, testing and introduction of the worlds first long term implantable micro sensor to give people with diabetes the modern tool they deserve for monitoring glucose levels.
Detecting glucose by the principle of the osmotic pressure holds promise of a glucose sensing technology that is suitable for both miniaturization and long term continuous monitoring in vivo without causing patient discomfort or reducing quality of life. It also offers several major advantages compared to current blood glucose measurement technologies.
Our headquarter is located in Bergen, Norway. The research and development is performed through our research partner across Europe.
Lifecare AS (Ltd.) is listed on Oslo Stock Exchange (LIFE-ME), and has been dedicated to the research and development of medical sensors for health monitoring since 06/07.
The Sencell-technology is protected by patents owned by Lifecare A/S (LIFE-ME). These patents are granted until year 2030 and new patents are pending.
Proof of concept of the proprietary osmotic pressure sensing technology has been successfully performed in two preclinical trials 2016 – 2017, proving that the pressure technology is able to track interstitial glucose and providing stable references.
Further miniaturization of the injectable glucose sensor highlights the planned device evolution and the accuracy of the employed 3D nanosensor technology measurement system. Data shows that the Sencell technology probably employs the smallest MEMS based pressure sensor in the world, with a reliable reproducibility of measurement results and a pressure resolution, which should lead to a resolution of glucose differences higher than CGM-devices currently on the market.
Lifecare is now continuing the development of a wireless sensor prototype suitable for first long term human clinical.
MBA from American Graduate School of International Management
Managing Director of Lifecare since 2012
Previously held senior management, operational and director positions in leading enterprises
Managed and participated in major national and international companies and projects
Private investor & adviser
Former CEO & partner at Borea
Head of Norwegian Equities at Nordea Invest Mgmt.
Portfolio manager at DNB
Portfolio manager at Investa
Board member in several companies
Chairman and CEO of Osmotex AG
Board member in several companies
LL.M. from the University of Bergen Norway
Practice as Lawyer in Norway
Member of the Lifecare BoD since 2011
Managing Director of PFÜTZNER Science & Health Institute GmbH, Diabetes Center & Practice, Mainz/Germany, since 2013
Honorary Professor of Applied Clinical Research for the University of Applied Sciences, Bingen/Germany, since 2007
Over 25 years of pharmaceutical and device development experience
Scientific Project Manager sciema UG, Mainz/Germany, since 2014
Post Doctoral Fellow at German Primate Centre, Göttingen/Germany, 2008 - 2010
PhD at the Department of Neurology, Georg-August-University, Göttingen/Germany, 2003 – 2007
CEO of DEVmedical UG, Oldenburg Germany
Senior Consultant Sensor Solutions
Head of Technology for MEMS/NEMS Sensor Development for Medical and Industrial Sensor Solutions 2016-2019
PhD at the Department of Physics in Sensor Development for Fundamental Research at University of Oldenburg, Oldenburg/Germany 2011-2015
International operating consultant for drug and device development, strategy as well as clinical and medical affairs in the medtech and pharma business.
Previously global Medical Director Devices in the diabetes division at Sanofi
Held management positions in several biotech and technology companies.
Over 20 years of experience in the pharma and medtech business
Clinical professor of Medicine, UCSF
Medical Director, INST
Chairman, i.a. DTM and ADA
Chaired i.e. FDA, NASA, US army, NIH, NSF
Consulting i.e. Sanofi, Google and Insulin
Partner and Scientific Consultant, Profil
Published 160 research articles
Awarded ”Leadership in Diabetes Technology”
Charing the EU founded project ”AP at home”
Professor of Internal Medicine and Endocrinology, University of Oslo
Senior consultant in Endocrinology, Dep. of Transplantation Medicine, Rikshospitalet, Oslo University Hospital
Chairman Advisory Board, Norwegian Diabetes Association
Professor for experimental solid state physics
Stefan Lyson professor of physics
Member Board of Trustees Beilstein-Institut, Frankfurt am Main
Member Scientific Advisory Board Frankfurt Institute of Advanced Studies
Member Scientific Advisory Board Austrian Centre for Electron Microscopy and Nanoanalysis
Member Senate of the Goethe University, Frankfurt am Main
- 170 peer-reviewed publications
The research and development is performed through our research partner across Europe. Our partners are all rated global experts in their field.
We take our role in developing the next generation of diagnostics healthcare platform and sensor solutions seriously.
digid is engaged in several research projects involving excellent international research partners as well as well-established technology providers.digid is developing a new kind of diagnostics healthcare platform solution through a proprietary combination of sensorics, biotech, A.I. and software that will, for the first time enable real-time identification of different biomarkers.
At the very core of digid ´s development, is a proprietary biosensor in combination with specifically designed receptors and digid´s Healthtech App as well as a fully integrated, A.I. powered Data Platform for real-time diagnostics of multiple human biomarkers.
This custom, real-time diagnostics procedure enables the identification of multiple human biomarkers in real-time and gives users / patients personalized recommendations on how to improve the current state of wellbeing. This can be a recommended doctor visit with a subsequent therapeutical treatment, specific nutritional supplements or other personalized recommendations to improve wellbeing and the current health-state
Cambridge Consultants (CC) is a world-class supplier of innovative product development engineering and technology consulting. Working from laboratories in Cambridge, UK, and Boston, USA, they have all the in-house skills needed to create an innovative concept right the way through to taking a product into manufacturing. Most of their projects deliver prototype hardware or software and trials production batches. Their technology consultants can help maximizing a product portfolio and technology roadmap.
CC works with some of the world’s largest blue-chip companies as well as with some of the smallest, innovative start-ups who want to change the status quo fast. Founded over 50 years ago, CC combines exceptional people, proven processes and excellent facilities, backed by an enviable track record of creating world-firsts, to deliver real value to our clients.
CC provides engineering product development services from idea conception to transfer to production to deliver innovative solutions with:
Reduced time to market
Increased return on investment
Ranked 6th in the UK by the Guardian University Guide 2020
Awarded Gold in the Teaching Excellence Framework 2017
87% of our research is classed as world-leading or internationally excellent by the most recent Research Excellence Framework 2014
PFÜTZNER Science & Health Institute deliver research at the highest level, incl
Centre for clinical studies (phases II – IV)
Centre for medicinal/medical product studies (incl. CE studies)
Laboratory studies pursuant to ISO15197:2013 for blood glucose monitoring systems
Performance/preference studies for medical products
Strategy and performance of clinical investigations